NCT05610332View on ClinicalTrials.gov

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2027

Conditions

Locally Advanced Gastric Cancer

Interventions

DRUG

Camrelizumab

Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.

DRUG

Albumin Taxol

Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle

DRUG

FLOT scheme

"Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w"

Trial Locations (2)

350000

Fujian Medical University Union Hospital, Fuzhou

Unknown

Department of Gastric Surgery, Fuzhou

All Listed Sponsors

lead

Fujian Medical University

OTHER

NCT05610332 - Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | Biotech Hunter | Biotech Hunter